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Human PTHrP gene displays a complex organization with nine exons producing diverse mRNA variants
due to alternative splicing at 50 and 30 ends and the existence of three different transcriptional promoters
(P1, P2 and P3), two of which (P2 and P3) contain CpG islands. It is known that the expression of PTHrP
isoforms may be differentially regulated in a developmental stage- and tissue-speciﬁc manner. To search
for novel molecular markers of stemness/differentiation, here we have examined isoform expression in
fat-derived mesenchymal stem cells both maintained in stem conditions and induced toward adipo- and
osteogenesis. In addition, the expression of the splicing isoforms derived from P2 and P3 promoters was
correlated to the state of methylation of the latter. Moreover, we also performed a quantitative evaluation
of intracellular and secreted PTHrP protein product in undifferentiated stem cells and in parallel cultures
at various differentiation stages. The data obtained indicate that from the stemness condition to that of
osteo- and adipo-genic differentiated cells, the expression of isoforms becomes increasingly selective,
thereby being a potential gene signature for the monitoring of cell stem or committed/differentiating
state and that the switching-off of PTHrP isoform expression is mostly promoter methylation-dependent.
Moreover, PTHrP intracellular retention is down-regulated in osteo-differentiating cells whereas the
secretion of the protein in the extracellular medium is up-regulated with respect to stem cells, thereby
suggesting that these variations of the intracellular and extracellular levels of PTHrP could potentially be
enclosed in the list of the available protein signature of osteogenic differentiation.
 2013 Published by Elsevier Masson SAS.
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951. Introduction
Mesenchymal stem cells (MSC) are a heterogeneous population
of stem cells with capacity to differentiate into mesodermal cell
lineages including osteocytes, adipocytes and chondrocytes, and
non-mesodermal cell lineages, e.g. neurons, insulin-producing andP, bone morphogenetic pro-
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108epithelial cells [1,2]. The use of somatic stem cells, particularly due
to their ability to be easily expanded ex vivo and the reduced
involvement of ethical and immunogenic issues, is one of the most
promising areas of research about tissue regeneration. Apart from
bone marrow and umbilical cord blood, adipose tissue has proven
to serve as source of adult stem cells with multipotent properties
[3e5], which can be harvested in relative abundance by modern
liposuction techniques under local anesthesia [6].
The multipotentiality of MSC is closely linked to their thera-
peutic interest, in that these cells might ﬁnd utilization in cell
therapy and tissue engineering. As an example, a better compre-
hension of the cellular and molecular mechanisms of differentia-
tion of adipose and bone tissue would be respectively useful to
develop innovative strategies to prevent and treat the obesity, that
results from excess white adipose tissue, and its related disorders,
and to improve bone regeneration thus by-passing the numerous
problems associated with reconstructive orthopedic surgery [7].
The different phases of the adipo- and osteo-differentiation
processes have been examined thoroughly and speciﬁc signalinging human mesenchymal stem cells: Transcript isoform expression,
://dx.doi.org/10.1016/j.biochi.2013.06.014
109
110
A. Longo et al. / Biochimie xxx (2013) 1e92
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
BIOCHI4209_proof ■ 30 June 2013 ■ 2/9pathways involved, such as those of Wnt and BMP, as well as
transcription factor families playing a central role in the of adipo-
genesis (e.g. Runx2 and Osterix) and osteogenesis (e.g. CCAAT/
enhancer binding proteins, peroxisome proliferator-activated re-
ceptors and sterol regulatory element binding proteins) have been
identiﬁed [e.g. Refs. [8e11]]. However, a complete scenario of these
differentiation events is far to be reached, and speciﬁc markers for
the characterization of deﬁned differentiation steps, especially the
earlier ones, are still lacking. In light of the interest on novel mo-
lecular signatures that can be utilized to monitor the stem,
committed or pre-differentiated state of cells, here we focused our
interest on some aspects of the expression and production of
parathyroid hormone-related protein (PTHrP), a well-known
regulator of proliferation, differentiation and apoptosis of normal
and neoplastic cells [e.g. Refs. [12e17]], whose activity on the
modulation of chondrogenic differentiation by adult stem cells has
been reported [e.g. Refs. [18,19]].
PTHrP is the product of a single gene which is located in the
short arm of human chromosome 12. It spans over 15 kbases of DNA
and displays a complex organization with nine exons undergoing
alternative splicing and producing diverse mRNA variants. Three
PTHrP transcriptional start sites have been reported, i.e. two TATA
box promoters, 50 to exons I and IV (named P1 and P3, respectively)
and a GC-rich promoter, 50 to exon III (named P2). The P2 promoter
contains a high percentage of CpG dinucleotides in an island up-
stream of exon III and CpG sites are present also in P3 promoter
[20,21]. As summarized in Table 1, different splicing events are
observed at the 50 terminus according to the promoter chosen to
initiate transcription. In addition, alternative splicing of exons at 30
end generates multiple PTHrP transcripts which encode three iso-
forms of the mature peptide of 139, 173 and 141 amino acids which
differ in their C-terminal regions. These protein isoforms are then
subjected to post-translational endoproteolysis into smaller
bioactive forms which have been either immunodetected or iso-
lated from conditioned media of normal and neoplastic cells and
are endowed with individual functions [22e24]. The presence of
three promoters and 50 and 30 terminus alternative splicing in-
dicates that the expression of PTHrP isoforms may be differentially
regulated in a developmental stage- and tissue-speciﬁc manner
[25e30].
Even though the PTHrP expression and biological role have been
extensively studied in many cell types, the expression of its tran-
script variants by MSC is so far poorly understood. Therefore, in
order to extend the knowledge of the biological signiﬁcance of
PTHrP differential regulation and to investigate whether selected
PTHrP isoforms may represent novel molecular signatures associ-
ated to stemness/differentiation state, the main aim of this study
was to examine the time-course expression of the splicing isoforms
of PTHrP in fat-derived MSC both maintained in stem conditions
and induced toward adipo- and osteo-genesis. In addition, the
expression of the splicing isoforms derived from P2 and P3 pro-
moters by MSC, was correlated to the state of methylation of these
promoters that contain CpG sites. A further set of analyses was also
performed for the quantitative evaluation of intracellular and
secreted PTHrP protein product in undifferentiated MSC and inTable 1
PTHrP mRNA variants produced by alternative splicing at the 50 and 30 ends.
Promoter Exons included at the 50 end Ever-present exons
P1 IeIIeIII VeVI
IeIII
I
P2 III VeVI
P3 IV VeVI
Please cite this article in press as: A. Longo, et al., PTHrP in differentiat
promoter methylation, and protein accumulation, Biochimie (2013), httpparallel cultures at various differentiation stages, in order to eval-
uate whether modiﬁcations of protein amounts, if any, can be
related to cell stem or differentiating state.
2. Materials and methods
2.1. Cell cultures and differentiation induction
The MSC used in the present investigation were cultured and
differentiated as described in Ref. [31]. In brief, MSC were obtained
from lipoaspirates of three different healthy donors and cultured in
DMEM supplemented with 10% fetal calf serum (FCS), 2 mM L-
glutamine, and 1% penicillin/streptomycin at 37 C and 5% CO2.
Adipogenic and osteogenic differentiation were checked via cyto-
chemical staining and molecular marker expression after four
weeks of culture, as described. At the end of each week, aliquots of
undifferentiated and differentiating cells were processed for DNA
and RNA isolation and for MICE assays (see following paragraphs),
whereas the conditioned media were supplemented with protease
inhibitors (100 mM leupeptin, 50 mM PMSF, 15 mM aprotinin and
5 mM EDTA) and stored at 80 C.
2.2. Genomic DNA isolation
Isolation of genomic DNA from undifferentiated and differenti-
ating cells was carried out with the PureLink Genomic DNA Kit
(Invitrogen, Carlsbad/CA, USA). The obtained DNA was quantiﬁed
by 0.8% agarose gel electrophoresis run in parallel with known
concentrations of salmon sperm DNA (EuroBio, Courtaboeuf, F) and
subsequent comparison of the intensities of the obtained bands.
2.3. RNA extraction and reverse transcription
Isolation of total RNA from undifferentiated and differentiating
cells was carried out with Tri Reagent (Sigma, St. Louis, MO/USA).
Before the reverse transcription, the total RNA was treated with
RQ1 RNase-free DNase (Promega, Madison, WI/USA) and its quality
and integrity checked through agarose gel electrophoresis in
denaturing conditions. The cDNAs were synthesized using Super-
Script II reverse transcriptase (Invitrogen) in the presence of 100 ng
random 6-mer primers (Sigma), 50 U RNase inhibitor (Promega)
and 0.5mMeach of dNTPs; reverse transcriptionwas carried out for
60 min at 42 C, followed by treatment with 2 U RNase H (USB,
Cleveland, OH/USA) for 20 min at 37 C.
2.4. Semi-quantitative multiplex (SM)- and methylation-sensitive
restriction endonuclease (MSRE)-PCR ampliﬁcation
SM-PCR was performed using 1 U RedTaq DNA polymerase
(Sigma)/ml, 200 mM each of dNTPs, 1 ml of the cDNA template ob-
tained from total RNA and 2.5 mM of the PTHrP splicing isoform-
and 18S-speciﬁc primers reported by Luparello et al. [28,29,32].
Preliminary assays were performed to determine the number of
cycles to keep ampliﬁcation within the exponential phase and
permit sufﬁcient visualization of the PCR product. The cycle proﬁleExons included at the 30 end/ protein isoform
VII/ 139 aa VIII/ 173 aa IX/ 141 aa
VII/ 139 aa VIII/ 173 aa IX/ 141 aa
VII/ 139 aa VIII/ 173 aa IX/ 141 aa
ing human mesenchymal stem cells: Transcript isoform expression,
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BIOCHI4209_proof ■ 30 June 2013 ■ 3/9chosen was 94 C for 2 min, followed by a product-speciﬁc number
of cycles of 94 C for 1 min, the appropriate annealing temperature
for 1 min, and 72 C for 1 min (5 min during the last cycle). PCR
products were analyzed by 2% agarose gel electrophoresis, visual-
ized by Gel Red staining (Biotium, Hayward, CA/USA) under UV
light, and the image captured in a digital support. The intensities of
the bands of interest, evaluated with SigmaScan software (SPSS,
USA), were normalized for those of 18S, and plotted in histograms
by SigmaPlot software (SPSS) to examine comparatively the pattern
and levels of the gene expression studied. As a positive, parallel
ampliﬁcation of cDNA from 8701-BC breast cancer cells cultured on
type I collagen, taken from laboratory stocks, was performed
[28,29].
MSRE-PCR was performed as described by Caradonna et al. [33].
Essentially, genomic DNA from undifferentiated and differentiating
cells was digested with HpaII and MspI methylation-sensitive re-
striction endonucleases (MSREs) and ampliﬁed by PCR in the
presence of primers ﬂanking three regions in PTHrP P2 and one
region in PTHrP P3 promoter containing cutting sites for MSREs
(Table 2). The reaction mixture contained 300 ng of digested DNA,
0.2 mM of each primer and 2.5 U Taq polymerase (Invitrogen); the
thermal cycle used was a denaturation step of 94 C for 4 min,
followed by 30 cycles of 94 C for 1 min, 60 C for 1 min, and 72 C
for 1 min (5 min during the last cycle). PCR products were analyzed
by 12% acrylamideebisacrylamide (29:1 ratio) gel electrophoresis
and visualized by SYBR Safe staining (Invitrogen) in a ChemiDoc
XRS apparatus (Bio-Rad, Hercules, CA/USA) and the image captured
in a digital support. The identity of the ampliﬁcation products was
checked by sequencing.
2.5. Microtiter immunocytochemical ELISA assay (MICE) assay
MICE assay was performed according to [34]. Essentially, un-
differentiated and differentiating cells, cultured in 96-well plates,
were ﬁxed with 50 ml HistoCHOICE Solution (AMRESCO, Solon, OH/
USA) and permeabilized with 0.05% saponin (Sigma) in Dulbecco’s
phosphate buffered saline (D-PBS). After quenching of endogenous
peroxidase with 0.03% H2O2 in DPBS and blocking of aspeciﬁc sites
with 10% FCS and 0.05% sodium azide in DPBS, cell preparations
were incubated overnight at 4 C with the primary antibody (anti-
PTHLP Ab-2, EMD Millipore, Billerica, MA/USA), raised against the
peptide corresponding to residues 34e53 of human PTHrP and
developed in rabbit. After incubation with peroxidase labeled anti-
rabbit secondary antibody, the immunoreactivity was revealed by
the addition of 100 ml of TMB soluble peroxidase substrate (Thermo
Fisher, Rockford, IL/USA) and the absorbance measured at
l ¼ 450 nm. After the evaluation of immunoreactivity, cell number
was assessed by staining with 0.05% Coomassie Blue dissolved in
40% methanol and 10% acetic acid, solubilization of the dye in 1%
SDS in DPBS, and measurement of the absorbance at l ¼ 650 nm.
TheMICE index was calculated as the ratio between the absorbance
value of immunoreactivity and that of Coomassie Blue labeling.Table 2
Primers used for ampliﬁcation of the CpG island-containing sites in PTHrP P2 and P3
promoters.
Site Primers 50-30 sequence Expected size (bp)
P2 S-II Forward GGTTCATGTGGGGAACTGG 215
Reverse CCCAGTCCTGATCTCCTGG
P2 S-III Forward TGTGGCCTCGTACAAGTCC 502
Reverse CTGGAGGAACTGCCTCAGG
P2 S-IV Forward CAGGAGACTCCAGAGAAGG 456
Reverse CTCTGGACTTGTACGAGGC
P3 Forward AGCTGACTTCAGAGGGGGAA 370
Reverse AGGGCATCTCCCAAGTTGAA
Please cite this article in press as: A. Longo, et al., PTHrP in differentiat
promoter methylation, and protein accumulation, Biochimie (2013), http
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Dot blot was performed as described in Ref. [35]. Essentially,
aliquots of 200 ml of media stored at80 Cwith protease inhibitors
as mentioned above, derived from undifferentiated and differen-
tiating cells were loaded and adsorbed onto the nitrocellulose
membrane. Aspeciﬁc sites were blocked by soaking in 5% bovine
serum albumin dissolved in Tris-buffered saline-Tween 20 (TBS-T:
150 mM NaCl, 20 mM TriseHCl pH 7.5, 0.05% Tween20). After in-
cubation with the primary (anti-PTHLP Ab-2, EMD Millipore) and
the secondary anti-rabbit antibody conjugated with alkaline
phosphatase, the spots were identiﬁed by staining the membrane
with BCIP/NBT liquid substrate system (Sigma), the image captured
in a digital support and spot intensities evaluated with Image J
software.
2.7. Statistical analysis
The data are presented as mean  s.e.m. The experiments were
performed at least in triplicate for each donor. A software-assisted
Student’s t test was performed (SigmaStat v.2.0, Jandel Scientiﬁc,
USA) and p < 0.05 was taken as the minimal level of statistical
signiﬁcance.
3. Results
3.1. Expression of PTHrP splicing products in osteo- and adipo-
differentiating MSC
RNA samples isolated at either day 7, 14, 21 or 28 from the three
MSC preparations cultured with or without differentiation in-
ducers, were subjected to reverse transcription and the cDNA ob-
tained ampliﬁed in the presence of the speciﬁc primers.
In a ﬁrst set of experiments the expression of 30 end splicing
variants, coding for the three PTHrP isoforms of 139, 141 and 173
amino acids, was checked. As shown in Fig. 1A, the splicing isoform
encoding for PTHrP 1e139 appeared to be selectively expressed by
undifferentiated cells. On the other hand, when the expression of
1e173 splicing isoformwas analyzed (Fig. 1B), a positive signal was
visualized in all samples, derived fromboth undifferentiated, osteo-
and adipo-induced MSC. These results suggest that expression of
1e139 splicing variant might be considered a stemness marker for
MSC, whereas the 1e173 splicing isoform appears to be the pre-
dominant variant expressed in the model systems under study. In
addition, as shown in the histograms, the expression levels of
PTHrP 1e173 in all preparations from adipo-differentiating cells
were always lower than those from undifferentiated cells, thereby
indicating that PTHrP 1e173 down-regulation might be considered
an adipo-differentiation speciﬁc feature. Conversely, we observed a
higher level of expression of this transcript in osteo-differentiating
vs. undifferentiated cells, suggesting that the up-regulation of this
30 end splicing isoform might be considered as a novel molecular
marker of osteo-induction. No band of 145 bp, indicative of the
presence of the splicing variants encoding for PTHrP 1e141 isoform,
could be observed after ampliﬁcation of all cDNA preparations (data
not shown), indicating that this splicing event is not occurring in
MSC both cultured in stem conditions and addressed to differen-
tiation toward the adipo- and osteo-genic lineage.
In a second set of experiments, the expression of the transcript
isoforms that are produced from either of the three promoters of
PTHrP gene, i.e. P1, P2 and P3 in undifferentiated and
differentiation-induced cells, were analyzed. Concerning the iso-
form produced starting from P1 promoter, it is known that the
ampliﬁcation with speciﬁc primers gives rise to different bands
depending on the exons enclosed in the transcript. In fact, a band ofing human mesenchymal stem cells: Transcript isoform expression,
://dx.doi.org/10.1016/j.biochi.2013.06.014
Fig. 2. Expression levels of PTHrP 50 end mRNA splicing isoforms produced starting
from P1 and P3 promoters in undifferentiated and differentiating MSC. A) PCR
ampliﬁcation of the cDNA fragment of the isoform produced starting from P1 promoter
from preparations of undifferentiated () and osteo-differentiating (þ) MSC at day 7,
14, 21 and 28 from plating, and 8701-BC cells as a positive control, showing the
presence of the sole band of 520 bp. Below, the ampliﬁcation of 18S cDNA is shown.
The electrophoretic marker in the ﬁrst lane is 100 bp ladder (Invitrogen). A similar
result was obtained when cDNA preparations from adipo-differentiating MSC were
utilized (data not shown). Agarose gel 2%, Red Gel staining. The data presented are
representative of 1 donor out of 3. B) Histogram showing the time-dependent mod-
ulation of the expression levels of the PTHrP mRNA isoform produced starting from P3
promoter. The histogram reports a prototypic example of the normalized band in-
tensities for undifferentiated MSC, since no ampliﬁcation signal was observed in
preparations from both osteo- and adipo-differentiating MSC. Data are presented as
mean  s.e.m. of triplicate experiments. *p < 0.05.
Fig. 1. Expression levels of PTHrP 30 end mRNA splicing isoforms for 1e139 and 1e173
protein variants in undifferentiated and differentiating MSC. (A) Histogram showing
the time-dependent modulation of the expression levels of PTHrP 1e139 mRNA iso-
form. The histogram reports a prototypic example of the normalized band intensities
for undifferentiated MSC, since no ampliﬁcation signal was observed in preparations
from both osteo- and adipo-differentiating MSC. (B) Histograms showing the time-
dependent modulation of the expression levels of PTHrP 1e173 mRNA isoform in
cDNA preparations from undifferentiated (black boxes) osteo- (gray boxes, top) and
adipo-differentiating MSC (gray boxes, bottom) at day 7, 14, 21 and 28 from plating.
Data are presented as mean  s.e.m. of triplicate experiments. *p < 0.05.
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BIOCHI4209_proof ■ 30 June 2013 ■ 4/9739 bp is obtained when the transcript contains exons IeIIeIII,
whereas bands of 520 and 406 bp are obtained when the transcript
contains exons I and III, or exon I only, respectively [25]. As shown
in Fig. 2A, when the utilization of P1 was examined, a band of
520 bp was found, indicative of a transcript obtained with the
exclusion of exon II, in all cDNA preparations from undifferentiated
and differentiating MSC, thus indicating that this variant represents
the only 50 end splicing isoform synthesized from the P1 start site.
Concerning the P2 promoter-originating isoform, no band of
468 bp indicative of the transcript produced from this promoterPlease cite this article in press as: A. Longo, et al., PTHrP in differentiat
promoter methylation, and protein accumulation, Biochimie (2013), httpcould be observed (data not shown), thereby indicating that P2 is a
transcriptionally-inactive start site in MSC under all chosen
experimental conditions. On the other hand, after ampliﬁcation
with the speciﬁc primers for the P3-derived 50 end splicing variant
a positive signal could be observed only in cDNA preparations ob-
tained from undifferentiated MSC cultured for at least 2 weeks,
with a maximum peak of expression at day 21 from plating
(Fig. 2B). The results obtained indicate that the P1 promoter-related
transcript is the predominant form synthesized by undifferentiated
and differentiating MSC, and suggest that the expression of the P3-
derived isoform might be considered a stemness marker for MSC.
Since undifferentiated MSC appeared to utilize both the P1 and
P3 promoters as transcriptional start sites, in order to evaluate
whether one of the two promoters might be more prominently
committed for PTHrP transcription the efﬁciency of PCR ampliﬁ-
cation of the isoform-speciﬁc cDNA fragments was examined. The
results obtained indicate that the transcript derived from P1 pro-
moter was more expressed than that from P3, because the corre-
spondent band was already detectable after 35 cycles of
ampliﬁcation, while that from P3 needed more than 40 cycles,
following normalization of the datawith ampliﬁcation of 18S cDNA.ing human mesenchymal stem cells: Transcript isoform expression,
://dx.doi.org/10.1016/j.biochi.2013.06.014
Fig. 3. Time course of P2 promoter methylation in undifferentiated and osteo-
differentiating MSC. Methylation analysis of S-II, S-III and S-IV sites of PTHrP P2
A. Longo et al. / Biochimie xxx (2013) 1e9 5
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BIOCHI4209_proof ■ 30 June 2013 ■ 5/93.2. Methylation state of PTHrP P2 and P3 promoters in
undifferentiated and osteo-differentiating MSC
In light of the obtained data on PTHrP isoform expression
showing no P2 promoter-derived isoform in all preparations tested,
as well as the expression of the P3 promoter-derived transcript
isoform only in cDNA preparations from undifferentiated MSC, we
therefore examined the methylation status of some internal sites of
CpG island of P2 and P3 promoters, in order to check if the pro-
moters were hypermethylated and therefore the expression of the
splicing variants silenced, or, in the absence of hypermethylation,
whether the presence of insulators could be supposed. Only un-
differentiated vs. osteo-differentiating MSC cultures were taken as
a prototypic model systems for this part of the study.
MSRE-PCR was performed on genomic DNA isolated at day 7, 14,
21 and 28 from MSC cultured with and without osteogenic differ-
entiation medium. Before PCR ampliﬁcation, the DNA was pre-
treated with the methylation-sensitive endonucleases HpaII and
MspI, that recognize the same sequence 50-CCGG-30 and cleave the
CeC bond, but respond in a different way to the state of methyl-
ation of C. In particular, the cleavage of DNA by HpaII is prevented
by the presence of a 5-methyl group at the internal C residue of the
sequence CCGG, whereas MspI cleaves DNA irrespective of the
presence of a methyl group except when all the four C of the double
strand site are methylated [36]. Therefore, the sites unavailable for
cutting by both enzymes were considered as “strongly methylated
or hypermethylated”, whereas those available for cutting by both
MSREs as “unmethylated”. The condition in which only one MSRE
cleaved the DNAwas associated to a “partially methylated” site. The
subsequent PCR gives an ampliﬁed product only when the MSRE is
unable to cut DNA, leaving the template intact and suitable for
reaction.
Three sites located within the CpG island of PTHrP P2 promoter,
i.e. S-II, S-III and S-IV, were submitted to ampliﬁcation in the
presence of the speciﬁc primers. In preparations fromMSC at day 7
(Fig. 3A), the 215 and 502 bp ampliﬁcation product for S-II and S-III,
respectively, were visualized after electrophoresis in a poly-
acrylamide gel only in the undigested DNA sample, while no bands
were present in digested DNA preparations, thus demonstrating
that S-II and S-III sites were unmethylated. Regarding S-IV site, a
456 bp band was observed in both undigested and digested DNA
samples, thereby giving evidence of the strong methylation of this
site inhibiting the activity of both MSREs. Conversely, in osteo-
differentiating MSC at day 7, S-II, S-III and S-IV sites of the P2
CpG island were heavily methylated, as shown by the presence of
the ampliﬁcation bands in both undigested and digested DNA
preparations. In undifferentiated and osteo-differentiating MSC at
day 14 (Fig. 3B), S-II and S-III sites of CpG island were strongly
methylated, and S-IV sitewas partially methylated, as shown by the
ampliﬁcation product originating from the preparation of genomic
DNA from undifferentiated MSC restricted with MspI, and from
differentiating MSC restricted with HpaII. When S-II and S-III sites
were analyzed in samples isolated at day 21 (Fig. 3C), they appeared
to be strongly methylated in undifferentiated cells, as demon-
strated by the presence of all ampliﬁcation bands, whereas dis-
playing a partial methylation and a strong methylation state,
respectively, in osteo-differentiating cells owing to the presence ofpromoter in undifferentiated () and osteo-induced (þ) MSC at day 7, 14, 21 and 28
from plating. ND ¼ undigested DNA, H ¼ DNA digested with HpaII, M ¼ DNA digested
withMspI. The electrophoretic marker in lane 7 is the 50 bp ladder with 375 bp as “ﬂag
fragment” (Invitrogen). Twelve percent acrylamideebisacrylamide (29:1 ratio) gel
electrophoresis, SYBR safe staining. The data presented are representative of 1 donor
out of 3. Q2
ing human mesenchymal stem cells: Transcript isoform expression,
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BIOCHI4209_proof ■ 30 June 2013 ■ 6/9215 bp products in both the undigested and the HpaII-digested
sample (for S-II site), and of all three 502 bp bands (for the S-III
site). S-IV site was shown to be strongly methylated in all the
examined preparations and differentiating MSC at day 28 (Fig. 3D),
were proven to have strongly methylated S-II and S-III sites of CpG
island, since the ampliﬁcation bands could be observed in both the
undigested and digested DNA preparations. S-IV site was partially
methylated, since in undifferentiated MSC the ampliﬁcation prod-
uct was found in the preparation of genomic DNA restricted with
HpaII, while in differentiated MSC in that restricted with MspI.
For P3 promoter, the results of the ampliﬁcation of genomic DNA
from undifferentiated and osteo-differentiated cells at the end of
each of the four weeks are shown in Fig. 4. In agreement with gene
expression data, preparations from MSC at day 7, both undifferen-
tiated and differentiating, exhibited a band of about 370 bp both in
the undigested DNA sample and in that digested with HpaII and
MspI, thereby indicating that CpG sites were methylated. The same
electrophoretic pattern was shown by preparations of differenti-
ating MSC at days 14 and 28, whereas the CpG sites at day 21
appeared to be partially methylated. In the undifferentiated cells,
the sites under study were not methylated at day 21 and 28, while
a hypermethylation of C was observed at day 14 in all MSC prep-
arations tested, this being the only result in disagreement with
gene expression data.
3.3. Intracellular accumulation and extracellular secretion of PTHrP
protein product by osteo- and adipo-differentiating MSC
In a further set of assays, to complement the data on selected
PTHrP isoform expression as a putative molecular signature for
MSC stemness/differentiation state, the levels of intracellular
accumulation and extracellular secretion of the protein product of
PTHrP were studied, to check whether reliable differences could be
found between undifferentiated and differentiating cells.
Concerning intracellular accumulation, the comparative anal-
ysis of the MICE index in undifferentiated and osteo-differentiating
MSC suggested that the accumulation of the PTHrP protein product
during the four weeks of treatment with inducers of differentiation
was always lower than that found in undifferentiated cells (Fig. 5A).
On the other hand, when the same cells were induced toward
adipogenic differentiation, the intracellular accumulation of theFig. 4. Time course of P3 promoter methylation in undifferentiated and osteo-differentiatin
induced (þ) MSC at day 7, 14, 21 and 28 from plating. ND ¼ undigested DNA, H ¼ DNA digeste
100 bp ladder with 600 bp as “ﬂag fragment” (Invitrogen). Twelve percent acrylamideebis
representative of 1 donor out of 3.
Please cite this article in press as: A. Longo, et al., PTHrP in differentiat
promoter methylation, and protein accumulation, Biochimie (2013), httpprotein did not differ signiﬁcantly from that of the sample (data not
shown).
Extracellular secretion of PTHrP protein product was studied by
dot-blot assay on MSC conditioned media. The data obtained
showed that in the media of osteo-induced MSC the secreted
amounts of PTHrPwere always higher than in those harvested from
untreated cultures, except for the very early step of differentiation,
i.e. day 7 (Fig. 5B). Also in this case, when the same cells were
induced toward adipogenic differentiation, the extracellular
amount of the secreted protein did not differ signiﬁcantly to the
(data not shown).
4. Discussion
PTHrP is a widely-distributed polyprotein coded by a complex
transcriptional unit, involved in several tissue-speciﬁc differentia-
tion events in which a varying splicing pattern expression of PTHrP
mRNA has been reported. For example, in normal human amnion
the P2 promoter was proven to be preferentially used and PTHrP 1e
139 to result the major PTHrP mRNA expressed [37]. In another
study on 39 cases of tumors classiﬁed as inﬁltrating ductal carci-
noma of the breast, renal cortical carcinoma and lung tumor, and 7
samples of normal tissues (renal, lung and thyroid samples),
Southby and coworkers demonstrated that all breast tumor, and
both normal and tumor renal samples used each of the three 30
splicing pathways and therefore expressed mRNA specifying each
of the three PTHrP isoforms. Furthermore all tissues examined
contained mRNA for the 1e141 isoform, and the mRNA for the 1e
139 isoform was always present, except in one normal lung and in
one parathyroid adenoma sample. On the other hand, the produc-
tion of the 1e173 isoform was more variable. When the use of the
PTHrP promoters was investigated, in contrast to the more
restricted utilization of P1 and P2 promoters, P3-initiated tran-
scripts were detected in all tissue samples [25]. Also 8701-BC breast
cancer cells were proven to utilize different start sites and mRNA
splicing patterns for PTHrP transcription when they were cultured
onto different substrates such as reconstituted basement mem-
brane (Matrigel) or representative collagen components of the
breast tumor stroma [28], or when exposed to different extracel-
lular Ca2þ concentrations and treated with differentiation agents
for breast cells [29].g MSC. Methylation analysis of PTHrP P3 promoter in undifferentiated () and osteo-
d with HpaII, M ¼ DNA digested withMspI. The electrophoretic marker in lane 13 is the
acrylamide (29:1 ratio) gel electrophoresis, SYBR safe staining. The data presented are
ing human mesenchymal stem cells: Transcript isoform expression,
://dx.doi.org/10.1016/j.biochi.2013.06.014
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Fig. 5. Intracellular accumulation and extracellular secretion of PTHrP protein product
by undifferentiated and osteo-differentiating MSC. Histograms showing the time-
dependent modulation of A) the MICE indexes, indicative of the intracellular levels
of PTHrP, and B) the extracellular protein levels of PTHrP from dot blot assay data, in
cell preparations and conditioned media from MSC cultured in stem conditions and in
the presence of osteogenic differentiation medium for 4 weeks. The histogram in B)
indicate the ratio between the amounts secreted by differentiating vs. undifferentiated
cells. Data are presented as mean  s.e.m. of triplicate experiments. *p < 0.05.
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BIOCHI4209_proof ■ 30 June 2013 ■ 7/9Little is known about the expression and the accumulation of
PTHrP transcript isoforms in adult MSC either undifferentiated or
differentiating toward osteo- and adipo-genic lineages. The litera-
ture data focus, almost exclusively, on the effect of different PTHrP
protein domains on the osteo-, chondro- and adipo-genic potential
of MSC [e.g. Refs. [37e39]]. Here we report that PTHrP splicing
isoforms are expressed in MSC both undifferentiated and differ-
entiating. In particular, on the basis of the data obtained on the
three different cell cultures here studied the following panel of
expression of PTHrP transcript isoforms in the different experi-
mental conditions can be schematized (Table 3), indicating that
from the stemness condition to that of osteo- and adipo-genic
differentiated cells, the expression of isoforms becomes increas-
ingly selective, thereby being a potential target for the monitoringTable 3
Synopsis of PTHrP splicing isoforms expressed in undifferentiated, osteo- and adipo-diffe
Cells Promoter
used
Exons included
at the 50 end
Ever-present
exons
Ex
is
Undifferentiated MSC P1 IeIII VeVI V
P3 IV VeVI V
Osteo-differentiating MSC P1 IeIII VeVI V
(e
Adipo-differentiating MSC P1 IeIII VeVI V
Please cite this article in press as: A. Longo, et al., PTHrP in differentiat
promoter methylation, and protein accumulation, Biochimie (2013), httpof cell stem or committed/differentiating state. Noteworthy, liter-
ature data indicate that dexamethasone may down-regulate PTHrP
expression of adult stem cells in a dose-dependent manner [40].
Taking into consideration that the hormone is present in both
culture media used for MSC differentiation but in different con-
centration (1 mM for adipo-induction, 0.1 mM for osteo-induction), it
is conceivable that it might be responsible, at least in part, for the
decreased PTHrP expression observed in MSC addressed to adipo-
differentiation.
Interestingly, preliminary results obtained with dental follicle
MSC of wisdom teeth, isolated during routine dental surgery [41],
show that these cells use solely the P3 promoter for the expression
of splicing variants (Longo, Tobiasch and Luparello, unpubl. data),
thereby suggesting that MSC from different tissue sources may be
endowed with differing transcriptional programmings. Therefore,
caution must be exercised in generalizing the data arising from
experiments on MSC depending on their origin, since they should
not be considered as a single homogeneous cytotype.
The role of epigenetic modiﬁcations in PTHrP expression has
been the object of a limited number of literature reports. Using
normal and lung squamous carcinoma cells as model systems, the
study of the methylation status of CpG dinucleotides in the 50 re-
gion of the gene showed that in the former case the CpG islands
were completely unmethylated, whereas in neoplastic cells, two-
thirds of the CpG islands were substantially methylated. Reverse
transcriptase-PCR analysis showed that this heavy methylation did
not prevent expression of any of the three PTHrP gene promoters,
highlighting that in the model systems under study methylation
was not associated with inhibition of gene activity [20]. Results
obtained with a human model of mammary epithelial cell lines
differing in tumorigenicity and PTHrP expression, have suggested
that the methylation status of speciﬁc CpG dinucleotides in the P2
promoter is the dominant mechanism involved in silencing of
PTHrP expression rather than the overall methylation of the CpG
island. Methylation of the PTHrP P2 promoter might represent a
potential marker of breast cancer progression and be used to
evaluate the metastatic potential of breast tumors [42].
In our study, the lack of P2 promoter-deriving transcription in
MSC under all experimental conditions, as well as of P3 promoter-
deriving transcription in differentiating MSC, prompted to enter
more into details through epigenetic analyses. The analysis of the
methylation status of the S-II, S-III and S-IV sites in CpG islands of
the P2 promoter in osteo-induced MSC from one donor by MSRE-
PCR showed a predominant hypermethylation or partial methyl-
ation at these sites. These data, therefore, may be related to those
obtained on P2 promoter-derived splicing isoform expression by
MSC, which had demonstrated that this transcript was not
expressed by cells under every culture condition, and suggest that
the CpG islands contained in the P2 promoter is of prime impor-
tance in regulating gene expression, consequently excluding the
hypothesis that these sites can accommodate a sequence insulator.
Concerning the CpG site of the P3 promoter, in agreement with
gene expression data, a condition of strong methylation was foundrentiating MSC.
ons included at 30 end/ size of
oform protein
Resulting mRNA and potential protein
isoforms
II/ 139 aa VIII/ 173 aa Four transcript isoforms, potentially
two protein isoformsII/ 139 aa VIII/ 173 aa
II/ 139 aa
arly time only)
VIII/ 173 aa Two transcript isoforms, potentially
two protein isoforms
III/ 173 aa One transcript isoform, one protein
isoform
ing human mesenchymal stem cells: Transcript isoform expression,
://dx.doi.org/10.1016/j.biochi.2013.06.014
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BIOCHI4209_proof ■ 30 June 2013 ■ 8/9in all four weeks of differentiation, whereas, in the undifferentiated
cell counterpart, hypermethylation was present at day 7, whereas
demethylation at day 21 and 28. The only result discordant with the
previously-obtained gene expression data is related to the strong
methylation of P3 promoter in all samples of undifferentiated MSC
at day 14. Although further validation of this result in other MSC
preparations might be necessary, if conﬁrmed this means that such
hypermethylation is unable to inhibit the expression of the splicing
isoform in this stage of the cell culture. Additional studies will be
therefore performed to understand the true role of P3 CpG sites,
even testing the hypothesis that can accommodate insulator
sequences.
In search for molecular markers relevant in the early monitoring
of the correct differentiation progress of MSC, we also evaluated
whether differences could be found in the rate of intracellular
accumulation and/or extracellular secretion of the protein product
of PTHrP. The combined data obtained from MICE and dot blot as-
says have put in evidence that PTHrP intracellular retention is
down-regulated in osteo-differentiating MSC which display a
higher level of secretion of the protein in the extracellular medium
with respect to stem cells, except for the early differentiation stage,
i.e. the ﬁrst week of osteo-induction. When adequately conﬁrmed,
these variations of the intracellular and extracellular levels of
PTHrP could potentially be enclosed in the list of the available
protein signature of osteogenic differentiation.
5. Conclusion
In conclusion, the collective data obtained have enlightened
some aspects in the complex and tightly-regulated biological pro-
cess of adipogenic and osteogenic differentiation by adult MSC, also
indicating that PTHrP expression and production might be
considered as signatures useful for monitoring the correct progress
of MSC differentiation. Further investigations will be useful to un-
ravel the molecular processes that regulate the differentiation
events of human somatic stem cells, which offer opportunities to
get more insight into questions in human biology and can promote
the advancement of clinical research helping the development of
new therapies and a better evaluation of biosecurity issues in
clinical trials.
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